Alexander A. Maini

TL;DR: This is a phase III randomised controlled trial to verify whether targeting a serum albumin level of ≥35 g/L in hospitalised patients with decompensated cirrhosis using repeated intravenous infusions of 20% HAS will reduce incidence of infection, renal dysfunction and mortality for the treatment period compared with standard medical care.

TL;DR: In a feasibility trial, administration of HAS increased serum levels of albumin in patients with AD/ACLF and appeared substantially under‐reported, indicating that ward‐based assessment of these parameters cannot be recorded with sufficient accuracy for use as a primary outcome in phase 3 trials.

TL;DR: This feasibility study aims to determine whether it is possible and safe to restore serum albumin to >30 g/L and maintain it at this level in patients admitted with acute decompensated cirrhosis using repeated 20% human albumin infusions according to daily albumin levels.

TL;DR: In this paper, the authors investigated the association between the innate immune response and death within 3 months of hospitalization and found that increased levels of interleukin 4 (IL4) in plasma collected at day 5 of treatment were associated with survival at 3 months.

TL;DR: There are no significant differences in activation marker expression or phagocytic capacity in the neutrophils obtained from each technique, and whole blood stimulation is the best model in experimentally challenging inpatient populations.